Avalo Therapeutics, Inc. Announces Changes to Its Board
December 16, 2021 at 02:32 am IST
Share
Avalo Therapeutics, Inc. appointed Steven J. Boyd, a current non-employee director of the Board, as Chairman of the Board, after unanimously voting to separate the Chief Executive Officer and Chairman roles. Mr. Boyd replaces Michael Cola as Chairman and Mr. Cola will continue to serve on the Board and as Chief Executive Officer of the Company. Dr. Magnus Persson will remain Lead Independent Director of the Board.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (AVTX-002) (anti-LIGHT monoclonal antibody (mAb)) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Quisovalimab shows reduction of Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT) levels, as well as a favorable safety and tolerability profile, in all indications studied including COVID-19 acute respiratory distress syndrome (ARDS), Crohn's Disease, and non-eosinophilic asthma (NEA).